{{item.videoDuration}}
{{item.title}}
{{item.text}}
{{item.videoDuration}}
{{item.text}}
Key takeaways:
- Memory shortages are creating new risks for medtech manufacturers, especially those reliant on legacy memory components.
- Legacy memory technologies used in many medical devices are being phased out, increasing the risk of supply disruptions and costly redesigns.
- Long regulatory approval timelines make component substitutions difficult, leaving companies vulnerable when parts reach end-of-life.
- Single-source supplier strategies are no longer sustainable, as allocation pressures and shortages continue to grow.
- Companies still planning around yesterday’s supply availability will face production stoppages, forced redesigns under regulatory pressure, and sustained margin erosion. Act now to secure supply, diversify sourcing, and modernize device platforms to maintain production continuity and avoid future disruptions.
Every medical device that processes an image, stores a patient record, or runs diagnostic software depends on memory chips. For years, these components of computer memory, Dynamic Random-Access Memory (DRAM) and NAND flash, were inexpensive and easy to source. Not anymore. Memory prices have surged by triple digits since early 20251. For medtech companies that have long treated memory as a commodity, the shift has been disorienting.
This is not a temporary spike—it is a structural reset in how memory is priced, allocated, and supplied and medtech is not positioned to absorb it.
This time, the market won’t self-correct
Three forces have converged to create a supply environment unlike anything in the modern history of semiconductor memory. First, AI infrastructure capital expenditure now exceeds $700 billion annually among the top cloud service providers, and the overwhelming share of that spending flows directly into memory procurement2. High-bandwidth memory alone consumes a disproportionate share of wafer starts while delivering a fraction of conventional DRAM bit output. Memory manufacturers are prioritizing production of higher-margin HBM chips for the booming AI market. As a result, fewer resources are available to other products such as DDR4 memory, which can lead to shortages, longer lead times, or higher costs for medical device manufacturers.
Second, the supplier base is structurally consolidated. Three companies are responsible for approximately 95% of DRAM production3 and have signaled to investors that they will not pursue aggressive commodity capacity expansion, instead prioritizing margin over volume. The few dominant market players have no economic incentive to relieve the shortage for low-priority buyers.
Third, geopolitical concentration compounds the risk. The vast majority of advanced DRAM fabrication is located in South Korea and Taiwan, regions subject to ongoing export controls, cross-strait tension, and natural disaster exposure. There is no meaningful DRAM fab capacity in the United States or Europe today.
Prior memory shortage cycles self-corrected within 5 to 11 quarters, driven by elastic demand from PC and mobile markets. The current upcycle is now past 6-8 consecutive quarters of price increases, and leading analysts project no meaningful relief before 2028. The market will not rebalance on a timeline that helps medtech.
Medtech Is uniquely vulnerable
Medtech companies face a compounding set of vulnerabilities that no other industry vertical matches. Medtech represents ~1% of global semiconductor demand, which places it at the bottom of allocation priority when suppliers ration output. The industry is overwhelmingly dependent on legacy memory nodes like DDR4, NOR flash, and older NAND geometries that manufacturers are actively winding down. DDR4 end-of-life strategies are accelerating across the supplier base, and most manufacturers have not altered their phase-out timelines.
The dependency is compounded by single-sourcing. More than 70% of medtech memory components are procured from a single qualified supplier, a legacy of procurement strategies optimized for cost rather than resilience.5 When that sole source announces an end-of-life notice, the clock starts on a requalification timeline that medtech cannot compress.
This is where the regulatory dimension becomes acute. FDA 510(k) and PMA pathways impose 12-to-24-month requalification cycles for component changes on Class II and Class III devices6. A seemingly minor substitution, such as swapping one DDR4 module for another from a different supplier, can trigger verification and validation requirements that stretch across multiple quarters. Device platforms designed for 10-to-15-year lifecycles are built on memory chips with 3-to-5-year commercial availability windows. The result is a structural mismatch: Parts disappear before replacements can be qualified. Lead times are now running 12 to 18+ months on critical memory components, device refresh costs are up more than 40%, and the “revalidation trap,” where legacy parts go end-of-life before new parts clear regulatory review, is becoming the defining supply chain challenge in medtech.
Four actions for medtech leaders to maintain production continuity
The four action areas below are not aspirational. They are the minimum threshold for medtech companies that intend to maintain production continuity through the end of the decade.
1. Secure supply now
Execute long-term agreements with memory suppliers before current contracts expire into a seller’s market. Conduct strategic buffer buys of DDR4, NOR flash, and legacy NAND ahead of confirmed end-of-life dates. Extend demand visibility signals to suppliers to at least 52 weeks. Medtech’s historically short planning horizons are no longer compatible with a supply environment where hyperscalers are locking in allocation years in advance.
2. Break single-source dependency
Launch alternate supplier qualification programs for every memory component classified as single-sourced. Dual-sourcing critical memory is no longer a best practice recommendation—it is an operational necessity. This requires engineering investment to qualify second sources, including accelerated testing protocols and updated device master records. The cost of dual qualification is a fraction of the cost of a production stoppage.
3. Accelerate platform migration
Begin proactive DDR5 and LPDDR5 redesign on the longest-lifecycle platforms first. The window to migrate from DDR4 on your own timeline, rather than being forced into it by an end-of-life notice, is narrowing quarter by quarter. Equally important: Invest in firmware abstraction layers that decouple device software from specific memory part numbers, enabling future component substitutions without full software revalidation.
4. Engage regulators proactively
The FDA’s Predetermined Change Control Plan framework, finalized under FDORA Section 515C, offers a pathway to pre-authorize specific component substitutions on Class III devices without requiring new marketing submissions for each change. Medtech companies should be building PCCPs that anticipate memory transitions now, not after the supply disruption forces an emergency filing. Industry coordination through the Advanced Medical Technology Association (AdvaMed) on standardized approaches to semiconductor component change notifications can amplify the effort across the sector.
Companies still planning around yesterday’s supply availability may face production stoppages, forced redesigns under regulatory pressure, and sustained margin erosion. The structural drivers behind this memory reset are clear, and the actions required to navigate it are knowable.
Medtech companies that treat memory as a strategic input will likely be better positioned to maintain supply continuity, manage cost pressure, and navigate regulatory constraints. The organizations that move early to secure supply, diversify sourcing, and modernize platforms are positioned to define the industry’s resilience in the years ahead.
Our team can help you convert semiconductor supply constraints into cross-functional strategies that protect margins, secure allocation, and build the regulatory and engineering flexibility to operate through a supply environment that is not going back to normal.
{{filterContent.facetedTitle}}
{{contentList.loadingText}}
{{contentList.loadingText}}
Follow us
